CheckMate 648 Update
CheckMate 648 Update: Phase III Study of First-line Nivolumab + CT vs Nivolumab + Ipilimumab vs CT for Advanced Esophageal Squamous Cell Carcinoma

Released: February 02, 2023

Expiration: February 01, 2024

Activity

Progress
1
Course Completed